Another of today's winners in the health-care space is Myriad Genetics (NASDAQ:MYGN), up 11% today after Medicare reimbursement cuts were announced. Though the cuts were harsh, they were lower than the market had been fearing, and Myriad came out on top as a result.
In this video, Motley Fool health-care analyst David Williamson discusses the Medicare cuts and the fact that they were still extremely severe, despite not being as severe as once feared. He also gives investors a few reasons not to love Myriad Genetics, despite the boost it got today from the market's expectations game.
David Williamson has no position in any stocks mentioned. The Motley Fool recommends Quest Diagnostics. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.